Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GNI Group ( (JP:2160) ) has issued an update.
GNI Group has acquired all shares of dental laboratory operator ZOO LABO, Inc., converting it into a consolidated subsidiary as of 29 December 2025, in a move to strengthen and expand its business base in Japan beyond headquarters functions. By integrating ZOO LABO’s CAD/CAM-driven dental prosthetics manufacturing with its existing Medtech capabilities and dental-use bone materials from Berkeley Advanced Biomaterials, GNI aims to accelerate digitalization in the dental field, create group synergies and enhance its medium- to long-term earnings, though the immediate impact on fiscal 2025 results is expected to be limited, with consolidation of ZOO LABO’s financials beginning in 2026.
The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2443.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. is a Japan-headquartered pharmaceutical group operating three segments—Pharmatech, Biotech and Medtech—across Japan, China, the United States and Australia, with the stated ambition of becoming a global mid-sized pharmaceutical company. Its Medtech arm already supplies bone materials for dental applications through Berkeley Advanced Biomaterials LLC, positioning the group at the intersection of pharmaceuticals, medical technology and dental healthcare.
Average Trading Volume: 1,272,579
Technical Sentiment Signal: Hold
Current Market Cap: Yen137.9B
For detailed information about 2160 stock, go to TipRanks’ Stock Analysis page.